低剂量西达本胺治疗原发免疫性血小板减少症的作用及机制
该研究通过C57BL/6J小鼠建立被动和主动ITP模型,给予不同剂量西达本胺(0、0.01、0.1、0.5、5 mg/kg)灌胃,每周两次;并在ITP患者外周血单个核细胞体外培养中验证。结果显示低剂量西达本胺(0.1 mg/kg)可提高小鼠血小板计数、降低出血相关死亡率、增加nTreg比例并降低血清IL-6水平,体外可增强Treg对效应T细胞增殖的抑制。
要点
- 低剂量西达本胺(0.1 mg/kg)可显著提高被动和主动ITP模型小鼠外周血血小板水平。
- 低剂量西达本胺可降低ITP主动模型小鼠出血相关死亡率。
- 低剂量西达本胺可提高ITP患者外周血单个核细胞培养体系中nTreg比例并增强Treg抑制功能。
核心结论
- 低剂量西达本胺可促进nTreg生成、增强Treg细胞的免疫抑制功能、降低IL-6水平,促进免疫耐受,对ITP有较好的治疗作用。
研究设计与样本
- 应用C57BL/6J小鼠建立ITP被动模型,灌胃给予0、0.01、0.1、0.5、5.0 mg/kg西达本胺,每周两次,观察治疗前后外周血血小板计数。
- 应用C57BL/6J小鼠建立ITP主动模型,灌胃给予0.1 mg/kg西达本胺,每周两次;4周后处死小鼠,流式细胞术检测脾细胞中CD4(+)CD25(+)Foxp3(+) nTreg比例,ELISA检测血清IL-6水平。
- 分离ITP患者外周血单个核细胞,与低剂量西达本胺共培养72 h后检测nTreg比例;免疫磁珠法分离CD4(+)CD25(+) Treg细胞与CD4(+)CD25(-)效应T细胞,以1∶4比例混合共培养,加入低剂量西达本胺干预,检测Treg对效应T细胞增殖的抑制作用。
主要发现
- 低剂量西达本胺(0.1 mg/kg)可明显提高ITP被动模型鼠外周血血小板水平。
- 低剂量西达本胺可显著提高ITP主动模型鼠外周血血小板水平,并降低出血相关死亡率。
- 低剂量西达本胺可显著提高ITP动物模型脾细胞中nTreg比例、降低血清IL-6水平。
- 低剂量西达本胺可显著提高ITP患者外周血单个核细胞培养体系中nTreg细胞比例、增强Treg细胞对效应T细胞增殖的抑制作用。
关键数值与推荐
- 低剂量西达本胺为0.1 mg/kg,灌胃给药,每周两次。
- 被动ITP模型西达本胺剂量梯度为0、0.01、0.1、0.5、5.0 mg/kg。
- Treg细胞与效应T细胞共培养比例为1∶4。
- 体外共培养干预时间为72 h。
临床怎么用
- 原文结论认为低剂量西达本胺通过促进nTreg生成、增强Treg免疫抑制功能、降低IL-6水平促进免疫耐受,对ITP有较好的治疗作用;体内动物研究提示低剂量西达本胺对ITP具有新的治疗作用。
局限性
- 原文结论指出体内动物研究提示低剂量西达本胺对ITP具有新的治疗作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the effect and mechanism of low-dose chidamide on the treatment of primary immune thrombocytopenia (ITP) . Methods: Passive ITP animal model and active ITP animal model were established by C57BL/6J mice. Different doses of chidamide (0, 0.01, 0.1, 0.5, and 5 mg/kg) were orally administrated twice a week for 120 hours in passive ITP mice. Secondly, low-dose chidamine (0.1 mg/kg) was given intragastrically administrated twice a week in active ITP mice. The platelet counts in the peripheral blood before and after treatment were detected. Four weeks later, mice were executed to prepare splenocyte suspension; natural regulatory T cells (CD4(+)CD25(+)Foxp3(+) nTreg cells) in splenocyte suspension were detected by flow cytometry. Serum IL-6 was measured by ELISA. Peripheral blood mononuclear cells from ITP patients were co-cultured with low-dose chidamide in vitro. After incubation for 72 hours, CD4(+)CD25(+)Foxp3(+) Treg cells of mononuclear cells was detected. CD4(+)CD25(+) Treg cells and CD4(+)CD25(-) effector T cells were separated by immunomagnetic beads. The Treg cells and effector T cells were co cultured in a ratio of 1∶4, and treated with low-dose chidamide. The proliferation of effector T cells was detected. Results: Chidamide with low dose (0.1 mg/kg) significantly improved platelet counts in passive ITP mouse model, as well as in the ITP active mouse model and reduced the mortality related to bleeding. Low-dose chidamide significantly increased the number and proportion of nTreg cells in mouse splenocytes, and decreased serum IL-6 level in active ITP mice. In ITP patients, low-dose chidamide also significantly expanded Treg cells in the PBMC culture system. Besides, the proliferation of effector T cells was suppressed. Conclusion: Low-dose chidamide enhances the proliferation of CD4(+)CD25(+)Foxp3(+) regulatory T cells to mediate immunosuppressive function. Serum IL-6 is inhibited for further immune tolerance. In vivo animal study suggestes that low-dose chidamide has a novel therapeutic effect on ITP. 目的: 探讨低剂量(0.1 mg/kg)西达本胺治疗原发免疫性血小板减少症(ITP)的作用及机制。 方法: ①应用C57BL/6J小鼠建立ITP被动模型,灌胃给予0、0.01、0.1、0.5、5.0 mg/kg西达本胺,观察治疗前后ITP小鼠模型外周血血小板计数。②应用C57BL/6J小鼠建立ITP主动模型,灌胃给予0.1 mg/kg西达本胺,观察治疗前后ITP小鼠模型外周血血小板计数;4周后处死小鼠,流式细胞术检测脾细胞中CD4(+)CD25(+)Foxp3(+)自然调节性T细胞(nTreg)比例并应用ELISA方法检测小鼠外周血IL-6水平。③分离ITP患者外周血单个核细胞,与低剂量西达本胺共培养72 h后检测nTreg细胞比例;免疫磁珠法分离CD4(+)CD25(+)调节性T细胞(Treg细胞)以及CD4(+)CD25(-)效应T细胞,将二者以1∶4比例混合共培养,加入低剂量西达本胺干预,检测Treg细胞对效应T细胞增殖的抑制作用。 结果: ①低剂量西达本胺可明显提高ITP被动模型鼠外周血血小板水平。②低剂量西达本胺可显著提高ITP动物模型外周血血小板水平,降低出血相关死亡率。③低剂量西达本胺可显著提高ITP动物模型脾细胞中nTreg比例、降低血清IL-6水平。④低剂量西达本胺可显著提高ITP患者外周血单个核细胞培养体系中nTreg细胞比例、增强Treg细胞对效应T细胞增殖的抑制作用。 结论: 低剂量西达本胺可促进nTreg生成、增强Treg细胞的免疫抑制功能、降低IL-6水平,促进免疫耐受,对ITP有较好的治疗作用。.
引用
- Zhao HY, Li DQ, Wang J, et al. [Effect and mechanism of low-dose chidamide on the treatment of primary immune thrombocytopenia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32447932. doi:10.3760/cma.j.issn.0253-2727.2020.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。